IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer
- Eric Faulkner, currently Sr. Vice President, CMC, appointed as Chief Technical Officer
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced the appointment of Qasim Ahmad, MD, as Chief Medical Officer. Dr. Ahmad joins IO Biotech from Novartis, where he most recently served as Senior Vice President, US Head of Clinical Development & Medical Affairs, for the Novartis Oncology business unit. A trained internist and clinical oncologist, he brings over two decades of successful strategic clinical development, medical affairs, and marketing authorization expertise to IO Biotech at a critical time in the company’s growth. Dr. Ahmad will be based in the United States, report to IO Biotech’s CEO, Mai-Britt Zocca, PhD, and be a member of the company’s executive team, effective immediately.
